Dexmedetomidine for Postoperative Sedation in Patients Undergoing Repair of Thoracoabdominal Aortic Aneurysms

• Status: Terminated
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to test the hypothesis that time on the ventilator and ICU length of stay will be shorter in TAA patients given postoperative sedation with dexmedetomidine compared to those given standard sedation. Secondary endpoints are: requirement for sedatives vasoactive drugs incidence of postoperative delirium and cost analysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborators: Hospira, Inc.; Hospira, now a wholly owned subsidiary of Pfizer
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• All Patients over age 18 undergoing non-emergent repair of type I-III TAA

Exclusion Criteria:

• Pregnancy

• Patients with hepatic impairment (increase of ALT or AST three times normal)

• Patient taking clonidine or tricyclic antidepressants.

• Patients taking opioids or benzodiazepines chronically (> 2 doses a day for > 1 month)

• Patients with second or third degree heart block without a pacer

• Patients undergoing emergency repair of TAA

• Intraoperative cardiac arrest

• Intraoperative massive blood loss (>10 l)